NCT02688101 is a Phase 1 clinical trial of DpC in Neoplasms, sponsored by Collaborative Medicinal Development Pty Limited.

Who is sponsoring NCT02688101?

NCT02688101 is sponsored by Collaborative Medicinal Development Pty Limited.

What drugs are being tested in NCT02688101?

Interventions in NCT02688101: DpC.

Is NCT02688101 still recruiting?

NCT02688101 is currently completed. Last updated 21 February 2019.

Last reviewed 2019-02-21 · How we verify

NCT02688101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors

Completed Phase 1 Last updated 21 February 2019

What this trial tests

Phase 1 trial testing DpC in Neoplasms in 14 participants. Completed in 26 October 2017.

Timeline

11 April 2016

Primary endpoint
26 October 2017

26 October 2017

Quick facts

Lead sponsor	Collaborative Medicinal Development Pty Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	11 April 2016
Primary completion	26 October 2017
Estimated completion	26 October 2017
Sites	4 locations across Australia

Drugs / interventions tested

DpC — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Collaborative Medicinal Development Pty Limited — full company profile →

Who can join

18 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter, open-label, dose-escalation and pharmacokinetic study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Metallodrugs are unique: opportunities and challenges of discovery and development.
Anthony EJ, Bolitho EM, Bridgewater HE, Carter OWL, et al · · 2020 · cited 372× · PMID 34123239 · DOI 10.1039/d0sc04082g
Iron and Cancer.
Torti SV, Manz DH, Paul BT, Blanchette-Farra N, et al · · 2018 · cited 335× · PMID 30130469 · DOI 10.1146/annurev-nutr-082117-051732
Targeting iron metabolism in drug discovery and delivery.
Crielaard BJ, Lammers T, Rivella S. · · 2017 · cited 279× · PMID 28154410 · DOI 10.1038/nrd.2016.248
Iron as a Central Player and Promising Target in Cancer Progression.
Jung M, Mertens C, Tomat E, Brüne B. · · 2019 · cited 195× · PMID 30641920 · DOI 10.3390/ijms20020273
Iron metabolism: pathophysiology and pharmacology.
Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, et al · · 2021 · cited 193× · PMID 34090703 · DOI 10.1016/j.tips.2021.05.001
Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.
Babak MV, Ahn D. · · 2021 · cited 125× · PMID 34440056 · DOI 10.3390/biomedicines9080852
A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.
Seebacher NA, Richardson DR, Richardson DR, Jansson PJ. · · 2016 · cited 81× · PMID 27906178 · DOI 10.1038/cddis.2016.381
The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.
Guo ZL, Richardson DR, Richardson DR, Kalinowski DS, et al · · 2016 · cited 77× · PMID 27678372 · DOI 10.1186/s13045-016-0330-x

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Collaborative Medicinal Development Pty Limited trials

Trials by the same sponsor.

NCT04313166 — Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 · Phase 2 · completed
NCT04082832 — CuATSM Compared With Placebo for Treatment of ALS/MND · Phase 2, PHASE3 · unknown
NCT03136809 — ALS Treatment Extension Study · Phase 1, PHASE2 · unknown
NCT03204929 — Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease · Phase 1 · completed
NCT02870634 — Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02688101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Collaborative Medicinal Development Pty Limited
Last refreshed: 21 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02688101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing